Drug
Gemcitabine-oxaliplatin regimen clinical trials
- studies test it
- 24
- open now
- 8
- in phase 3
- 4
- first study started
- 2004
Keep track of what changes. Save the gemcitabine-oxaliplatin regimen studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
24 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2004 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 22
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 20
Jiangsu HengRui Medicine Co., Ltd. (2) · Asan Medical Center (2) · Shanghai Zhongshan Hospital (1) · The First Affiliated Hospital with Nanjing Medical University (1) · Georgetown University (1) · Samsung Medical Center (1) · M.D. Anderson Cancer Center (1) · Gustave Roussy, Cancer Campus, Grand Paris (1)
Often tested with
Tested in the same studies.
Camrelizumab (2) · Immune Checkpoint Inhibitors (1) · Lenvatinib (1) · Apatinib (1) · FOLFOX-4 Regimen (1) · Gemcitabine (1) · Modified FOLFOX6 Regimen (1) · Docetaxel (1)
Studies
Open first, then newest update. How each study uses gemcitabine-oxaliplatin regimen is read from its arms, and is right about nine times in ten.
Testing it · 24
- A Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion Therapy for Biliary Tract CancerRecruitingPhase 2Haitao Zhao, MDNCT07854600Written as GEMOX Regimen
- A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCsRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06423170Written as Camrelizumab plus GEMOX
- Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular CarcinomaRecruitingPhase 2/3UNICANCERNCT06904170Written as HAIC (GEMOX)
- Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic CholangiocarcinomaRecruitingPhase 2University Hospital, MontpellierNCT03364530Written as Gemcitabine-Oxaliplatin Regimen
- Golidocitinib Combined With GemOx in RR PTCLNot yet recruitingPhase 2Ruijin HospitalNCT07279584Written as GEMOX
- A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.Not yet recruitingPhase 2Fujian Cancer HospitalNCT06654947Written as Surufatinib+Toripalimab+GEMOX
- Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBCRecruitingPhase 2Eastern Hepatobiliary Surgery HospitalNCT06013943Written as Envafolimab+Gemox
- Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell LymphomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT05381506Written as Orelabrutinib and Gemox
- A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTCCompletedPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT03092895Written as GEMOX
- Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCATerminatedPhase 2Peking UniversityNCT06739252Written as Gemcitabine Oxaliplatin and 5FU
- A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell LymphomaTerminatedPhase 1/2Antengene CorporationNCT04425070Written as GEMOX [gemcitabine+oxaliplatin]
- First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAICTerminatedPhase 2Shandong Cancer Hospital and InstituteNCT06370663Written as HAIC (GEMOX)
- Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell LymphomaTerminatedPhase 2Seoul National University HospitalNCT06941688Written as Decitabine with GemOx
- Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract CancerActive, not recruitingPhase 2Shanghai Zhongshan HospitalNCT05156788Written as PD-1+Lenvatinib+GEMOX
- SHR-1210 in Combination With GEMOX in Patients With Advanced BTCCompletedPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT03486678Written as SHR-1210+GEMOX
- SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's LymphomaStatus unknownPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT04948788Written as Gemcitabine-Oxaliplatin
- Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular CarcinomaWithdrawnPhase 2/3Guangxi Medical UniversityNCT02534337Written as GEMOX
- Molecularly Tailored Therapy for Pancreas CancerCompletedPhase 2Georgetown UniversityNCT01888978Written as Gem-OX
- Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial CarcinomaStatus unknownPhase 2Asan Medical CenterNCT01487915Written as GemOx
- Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib (Tarceva) in Advanced Biliary Tract CarcinomaCompletedPhase 3Samsung Medical CenterNCT01149122Written as Gemcitabine/Oxaliplatin
See all 24 studies that test gemcitabine-oxaliplatin regimen →
Given in every arm · 5 — gemcitabine-oxaliplatin regimen is usual care beside what is tested
- GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced CholangiocarcinomaRecruitingNot applicableTianjin Medical University Cancer Institute and HospitalNCT05215665Written as GEMOX Regimen
- Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract CancerCompletedPhase 1/2Institut du Cancer de Montpellier - Val d'AurelleNCT02386397Written as GEMOX
- Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic CholangiocarcinomaStatus unknownPhase 2Tianjin Medical University Cancer Institute and HospitalNCT05251662Written as GEMOX
- To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCLCompletedPhase 2Boehringer IngelheimNCT02624492Written as GemOx
- Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder CarcinomaStatus unknownPhase 2Shanghai Jiao Tong University School of MedicineNCT02836847Written as GEMOX